attr-cm

BEYONTTRA (acoramidis), the First Near-complete TTR Stabilizer (90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CMBEYONTTRA (acoramidis), the First Near-complete TTR Stabilizer (90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

BEYONTTRA (acoramidis), the First Near-complete TTR Stabilizer (90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

April 28, 2025 05:00 ET  | Source: BridgeBio Pharma, Inc. - The UK approval is based on positive results from…

3 weeks ago
Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM PatientsAttruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

- Attruby is the first and only approved product with aspecifying near-complete stabilization of TTR. Attruby has been…

6 months ago
Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM PatientsAttruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

- Attruby is the first and only approved product with aspecifying near-complete stabilization of TTR. Attruby has been…

6 months ago